This article first appeared in The Edge Malaysia Weekly on May 11, 2026 - May 17, 2026

GIIB Holdings Bhd’s (KL:GIIB) sudden 50% share price surge last Monday was an absolute head-scratcher. Just days earlier, its external auditors had slapped the technical rubber compound provider with a qualified opinion on its financial statement for FY2025 and issued a “going concern” warning, citing huge losses and a precarious cash position.

But the missing piece of the puzzle clicked into place after GIIB responded to an unusual market activity query from Bursa Malaysia. It revealed that it was in the midst of considering “a potential investment in a healthcare-related business”. It also said the proposal was still at a preliminary stage, with key details and terms yet to be finalised.

For seasoned market observers, it must have felt like déjà vu. GIIB had walked this path before, having jumped on the pandemic-era glove bandwagon. But that venture, far from becoming a new and robust revenue stream for the group, turned into the primary source of its current accounting headaches.

In fact, its auditors’ qualified opinion stems largely from its inability to verify the deconsolidation of the group’s glove unit and the recoverability of millions owed to the group. In short, the accounts are so messy the professionals cannot even confirm if the reported numbers are accurate.

On top of that, the group’s cash flow is negative and its balance sheet shows that short-term liabilities outweigh assets. The picture does not look pretty.

Can GIIB truly be lucky this time around? It is difficult to say at this stage because there is nothing to go on or to evaluate so far.

With the proposed investment still in its infancy, the market’s reaction at this point suggests nothing more than speculative fever. While the counter’s 16-sen price tag might look attractive to penny stock hunters, the auditors’ warning should serve as a flashing red light.

Save by subscribing to us for your print and/or digital copy.

P/S: The Edge is also available on Apple's App Store and Android's Google Play.